The Valley Desk

ArticlePulmonary pharmacology & therapeuticsPublished

Setting expectations with oral selexipag: an expert consensus-based approach on best practices to initiate, dose, titrate, and manage side effects (SEs) in patients with pulmonary arterial hypertension (PAH)

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Pulmonary pharmacology & therapeutics
Published
Subject terms
Humans; Acetamides; Pyrazines; Antihypertensive Agents; Administration, Oral; Dose-Response Relationship, Drug; United States; Pulmonary Arterial Hypertension; Recommendations; Guidelines; Best Practice; Selexipag
PubMed ID
41519430
Added to directory
Source checked

Report a correction or request removal